Biotech stocks went back and forth but managed to end the week with a gain. As usual, some stocks swung wildly in reaction to catalysts, primarily clinical readouts.
Aurinia Pharmaceuticals Inc AUPH 2.93% more than doubled in a single session after its lead drug aced a pivotal trial in lupus nephritis. Meanwhile, SAGE Therapeutics Inc SAGE 7.11% saw more than half of its market value wiped out due to disappointing late-stage data for its depression drug.
Here are the key catalysts for the unfolding week.
Conferences
American Epilepsy Society, or AES, 2019 Annual Meeting – Dec. 6-10 in Baltimore, Maryland
61st American Society of Hematology, or ASH, Annual Meeting – Dec. 7-10 in Orlando, Florida
San Antonio Breast Cancer Symposium, or SABCS, 2019 – Dec. 10-14 in San Antonio, Texas
European Society of Medical Oncology, or ESMO, Immuno-Oncology Congress – Dec. 11-14, in Geneva, Switzerland
61st American Society of Hematology, or ASH, Annual Meeting – Dec. 7-10 in Orlando, Florida
San Antonio Breast Cancer Symposium, or SABCS, 2019 – Dec. 10-14 in San Antonio, Texas
European Society of Medical Oncology, or ESMO, Immuno-Oncology Congress – Dec. 11-14, in Geneva, Switzerland
PDUFA Dates
The FDA is set to rule on Amgen, Inc.’s AMGN 0.15% ABP 710, a biosimilar to Johnson & Johnson’s JNJ 0.55% Remicade, which has been approved for multiple indications such as Crohn’s disease, ulcerative colitis, rheumatoid arthritis, psoriatic arthritis, plaque psoriasis and ankylosing spondylitis. The BsUFA date is set for Saturday.
Adcom Calendar
FDA’s Cardiovascular and Renal Drugs Advisory Committee will discuss Tuesday Correvio Pharma Corp’s CORV 39.81% NDA for Brinavess, or vernakalant HCl solution, ahead of the Dec. 24 PDUFA action date.
Clinical Readouts
ASH Presentations
Sunday
Orchard Therapeutics PLC – ADR ORTX 4.27% – Phase 1/2 data for OTL-103 in Wiskott-Aldrich syndrome
TG Therapeutics Inc common stock TGTX 7.29% – Phase 1/2 data for umbralisib in combination of AbbVie Inc ABBV 0.37%‘s Venclexta in chronic lymphocytic leukemia
GENMAB A/S/S ADR GMAB 1.33%: initial Phase 1 data for HexaBody-DR5/DR5 in solid tumors
Morphosys Ag MOR 1.42%: Phase 1 data for tafasitamab in diffuse large B-cell lymphoma
Uniqure NV QURE 2.28%: Phase 2b data for AMT-061 in hemophilia B
Autolus Therapeutics Ltd – ADR AUTL 0.27% – Phase 1 data for AUT02 in relapsed or refractory multiple myeloma
Bristol-Myers Squibb Co BMY 0.72%: updated Phase 1 data for liso-cel in chronic lymphocytic leukemia
Actinium Pharmaceuticals Inc ATNM 6.74%: Phase 1 data for actimab-A in combination with CLAG-M in relapsed or refractory acute myeloid leukemia
Portola Pharmaceuticals Inc PTLA 3.03%: interim Phase 2a data for cerdulatinib in refractory non-Hodgkin lymphoma and chronic lymphocytic leukemia
Rocket Pharmaceuticals Inc RCKT 13.47%: Phase 1 data for RP-L102 in Fanconi anemia
Fortress Biotech FBIO 7.01% and Mustang Bio Inc MBIO 0.52%: Phase 1 data for MB-106 in B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia
PDS Biotechnology Corp PDSB 12.8%: Phase 1 data for PDS0101 in head and neck cancer/human papillomavirus 16 infection
Sunesis Pharmaceuticals, Inc. SNSS 8.57%: Phase 1/2 data for vecabrutinib in advanced B-cell malignancies
Alpine Immune Sciences Inc ALPN 5.14%: Phase 1 data for ALPN-101 in healthy volunteers
Kura Oncology Inc KURA 2.63%: Phase 2 data for tipifarnib in relapsed or refractory peripheral T-cell lymphoma
Beigene Ltd BGNE 1.21%: Phase 3 data for zanubrutinib in first-line chronic lymphocytic leukemia or small lymphocytic leukemia
Autolus Therapeutics Ltd – ADR AUTL 0.27%: Phase 1 data for AUT03 in acute lymphoblastic leukemia
Blueprint Medicines Corp BPMC 5.26%: initial Phase 2 data for avapritinib in indolent and smoldering systemic mastocytosis
Eli Lilly And Co LLY 0.16%: Phase 1/2 data for LOXO-305 in refractory chronic lymphocytic leukemia, small lymphocytic lymphoma, non-Hodgkin’s lymphomas
Imv Inc IMV 4.14%: Phase 2 data for DPX-Survivac and Merck & Co., Inc. MRK 0.09%‘s Keytruda in diffuse large cell lymphoma
Monday
- bluebird bio Inc BLUE 1.53%: Phase 3 data for lentiglobin – HGB-212 in transfusion-dependent thalassemia and the β0/β0genotype and lentiglobin – HGB-207 in non-β0/β0 transfusion-dependent thalassemia
- Magenta Therapeutics Inc MGTA 2.39%: Phase 2 data for MGTA-456 in acute lymphoblastic leukemia
- CELYAD SA/ADR CYAD 5.14%: Phase 1 data for CYAD-01 in solid and hematologic cancers; Phase 1 data for CYAD-01 and chemotherapy in acute myeloid leukemia or myelodysplastic syndrome
- Achillion Pharmaceuticals, Inc. ACHN 0.33% and Alexion Pharmaceuticals, Inc. ALXN 6.02%: danicopan in paroxysmal nocturnal hemoglobinuria
- Seattle Genetics, Inc. SGEN 0.29%: Phase 1/2 data for ST-400 in beta thalassemia
- Agios Pharmaceuticals Inc AGIO 2.15%: Phase 2 data for AG-348 in pyruvate deficiency; updated Phase 1 data for ivosidenib and Bristol-Myers Squibb’s Vidaza in newly diagnosed acute myeloid leukemia with an IDH1 mutation
- Orchard Therapeutics: Phase 1 data for OTL-203 in MPS 1
- GENMAB: Phase 1/2 data for GEN3013 in B-cell lymphoma
- Kadmon Holdings Inc KDMN 10.27%: Phase 2 data for KD025-208 in chronic graft-versus-host disease
- Aprea Therapeutics Inc APRE 7.82%: Phase 2 data for APR-246 and Bristol-Myers Squibb’s azacitidine in TP53 mutated myelodysplastic syndrome and acute myeloid leukemia; Phase 2 data for APR-246 in combination with azacitidine in myelodysplastic syndromes
- Gamida Cell Ltd GMDA 0.2%: additional Phase 1 data for NAM-NK in non-Hodgkin lymphoma and multiple myeloma
- Bristol-Myers Squibb & bluebird bio: Phase 1 data for bb21217 in multiple myeloma
- Onconova Therapeutics Inc ONTX 19.82%‘: Phase 2 data for oral rigosertib and azacitidine in first-line high-risk myelodysplastic syndromes
- Forty Seven Inc FTSV 2.12%‘: Phase 1b data for 5F9 in combination with azacitidine for acute myeloid leukemia
- ImmunoGen, Inc. IMGN 0.64%‘: updated Phase 1 data for IMGN632 in acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm
- Calithera Biosciences Inc CALA 5.88% – Phase 2 data for telaglenastat in combination with azacitidine in myelodysplastic syndrome
- TG Therapeutics: Phase 1 data for TG-1701 in non-Hodgkin lymphoma and chronic lymphocytic leukemia
- Curis, Inc. CRIS 14.67%: updated Phase 1 data for CA-4948 in relapsed or refractory non-Hodgkin lymphoma
- ArQule, Inc. ARQL 1.63%: Phase 1 data for ARQL 531 in B-cell malignancies
- Xencor Inc XNCR 1.11%: initial Phase 1 data for XmAb1367 in chronic lymphocytic leukemia, small lymphocytic lymphoma
- MacroGenics Inc MGNX 4.59%: updated Phase 1 data for flotetuzumab in acute myeloid leukemia/myelodysplastic syndrome
- Constellation Pharmaceuticals Inc CNST 2.46%: additional Phase 2 data for CPI-0610 and Incyte Corporation INCY 0.52%‘s ruxolitinib in myelofibrosis
- Regeneron Pharmaceuticals Inc REGN 1.06%: updated Phase 1 data for REGN1979 in follicular lymphoma
- Stemline Therapeutics Inc STML 5.15%: Phase 1/2 data for SL-401 in myelofibrosis
- CTI BioPharma Corp CTIC 2.9%: Phase 2 dose-finding study of Pacritinib in myelofibrosis
- Geron Corporation GERN 0.66%: Phase 2/3 data for imetelstat in myelodysplastic syndromes
- Precision BioSciences Inc DTIL 6.21%: Interim Phase 1/2 data for PBCAR0191 in relapsed or refractory B-cell precursor acute lymphoblastic leukemia and R/R non-hodgkin lymphoma
Tuesday
Amgen, Inc. AMGN 0.15% & GENMAB: Phase 3 data for krypolis in multiple myeloma (late-breaker abstract)
Sanofi SA SNY 0.11%: Phase 3 data for sutimlimab in cardinal cold agglutinin disease
Bristol-Myers Squibb: Phase 3 data for oral azacitidine for acute myeloid leukemia maintenance
SABCS Presentations
MacroGenics and Zai Lab Ltd ZLAB 0.29% – oral presentation of detailed results from the second interim overall survival analysis form the SOPHIA study of margetuximab in patients with HER2-positive metastatic breast cancer who have been previously treated with anti-HER2-targeted therapies (date not confirmed)
Seattle Genetics – already-released Phase 2 data for Tucatinib ONT-380 in combination with Roche Holdings AG Basel ADR Common Stock RHHBY 0.36%‘s Herceptin and oral chemotherapy Xeloda in HER2+ metastatic breast cancer (Wednesday)
G1 Therapeutics Inc GTHX 11.49% – additional Phase 1b data for Lerociclib plus AstraZeneca plc AZN 0.1%‘s Faslodex in ER+ breast cancer (Wednesday)
OncoSec Medical Inc ONCS 1.36%: interim Phase 2 data for tavo in combination with Keytruda in triple-negative breast cancer (Thursday)
Oncternal Therapeutics Inc ONCT 2.27%: Phase 1 data for cirmtuzumab, in combination with Bristol-Myers Squibb’s Abraxane (Thursday)
Athenex Inc ATNX 7.97%: Phase 3 data for oraxol in metastatic breast cancer (Friday)
ESMO-IO Presentations
Gritstone Oncology Inc GRTS 7.96% – initial safety data from the Phase 1 study of GRANITE-001 in solid tumors (date not confirmed) as well as initial safety data from the Phase 1 data for SLATE-001 in solid tumors
BIOLINERX LTD/S ADR BLRX 13.24% – Phase 2a data for BL-8040 in combination with Merck’s Keytruda in pancreatic cancer (Friday)
Earnings
Twist Bioscience Corp TWST 6% (Wednesday, after the market close)
Veru Inc VERU 2.02% (Thursday, before the market open)
Applied DNA Sciences Inc APDN 3.14% (Thursday, after the market close)
Veru Inc VERU 2.02% (Thursday, before the market open)
Applied DNA Sciences Inc APDN 3.14% (Thursday, after the market close)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.